Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

[Liposomal bupivacaine-No breakthrough in postoperative pain management].

Authors:
Berit Otremba Hanns-Christian Dinges Ann-Kristin Schubert Wolfgang Zink Thorsten Steinfeldt Hinnerk Wulf Thomas Wiesmann

Anaesthesiologie 2022 Jul 25;71(7):556-564. Epub 2022 Apr 25.

Klinik für Anästhesie und Intensivtherapie Universitätsklinikum Marburg, Philipps-Universität Marburg, Baldingerstraße, 35033, Marburg, Deutschland.

One of the main limitations concerning the use of local anesthetics is due to their restricted duration of action. In recent years, liposomal formulations with prolonged release kinetics have been developed to extend the pharmacological duration of action of the 1‑stage peripheral regional anesthesia (single-shot procedure) and thus bring about a longer duration of action. The focus here is particularly on achieving postoperative freedom from pain for at least 24 h (or even better 48 h) and thus early mobilization of patients using on-demand medication causing (at most) minor local sensory blockade without causing motor impairments (at least that is the ideal). Therefore, methods of utilizing slow-release drugs as seen in liposomal carrier systems have experienced increasing scientific attention in the last few years. A common modern pharmacological example with a theoretically significantly longer duration of action is liposomal bupivacaine, an amide local anesthetic. Due to a multivesicular liposome structure, the retarded release of the active component bupivacaine HCl leads to a theoretical pharmacological effectiveness of up to 72 h. Previous studies consistently showed a safety profile comparable to conventional bupivacaine HCl. Liposomal bupivacaine has been approved by the U.S. Food and Drug Administration (FDA) under the trade name Exparel© (Pacira Pharmaceuticals, Parsippany, NJ, USA) since 2011; however, its use is currently limited to local wound infiltration, transverse abdominis plane (TAP) blocks, and interscalene nerve blocks of the brachial plexus. In 2020, the European Medicines Agency (EMA) also approved the use of liposomal bupivacaine for blockade of the brachial plexus or the femoral nerve and as a field block or for wound infiltration to treat postoperative pain. So far, studies on the clinical effectiveness of liposomal bupivacaine have been very heterogeneous and there have been no conclusive meta-analyses with sufficient rigor or significance. Recent systematic reviews and meta-analyses, combining the results of clinical studies regarding the analgesic efficiency of liposomal bupivacaine in different fields of application, consistently refuted any benefit of clinical relevance provided by the liposomal formulation. There is currently sufficient evidence to now end the ongoing debate around liposomal bupivacaine. The aim of this work is to give the reader a current, evidence-based overview of this substance.

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00101-022-01118-7DOI Listing
July 2022

Publication Analysis

Top Keywords

liposomal bupivacaine
24
duration action
16
liposomal
9
brachial plexus
8
bupivacaine hcl
8
wound infiltration
8
bupivacaine
8
postoperative pain
8
food drug
4
exparel© pacira
4
approved food
4
bupivacaine approved
4
drug administration
4
hcl liposomal
4
administration fda
4
fda trade
4
conventional bupivacaine
4
trade exparel©
4
parsippany usa
4
pacira pharmaceuticals
4

Keyword Occurance

Similar Publications

Extended Release of Bupivacaine from Temperature-Responsive Hydrogels Provides Multi-Day Analgesia for Postoperative Pain.

Authors:
John M Heffernan Alex C McLaren Christopher M Glass Derek J Overstreet

Pain Med 2022 Aug 9. Epub 2022 Aug 9.

Sonoran Biosciences, Tempe, AZ, USA.

Objective: A local anesthetic that provides analgesia lasting at least three days could significantly improve postoperative pain management. This study evaluated the analgesic efficacy and safety of an extended-release formulation of bupivacaine based on the injectable hydrogel carrier poly(N-isopropylacrylamide-co-dimethylbutyrolactone acrylamide-co-Jeffamine M-1000 acrylamide) (PNDJ).

Methods: The efficacy of PNDJ containing 4% bupivacaine (SBG004) given by peri-incisional subcutaneous injection (SBG004 SC) or wound filling instillation (SBG004 WF) was evaluated compared to saline, liposomal bupivacaine, bupivacaine collagen sponge, bupivacaine-meloxicam polyorthoester, and bupivacaine HCl in a porcine skin and muscle incision model. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Liposomal Bupivacaine Decreases Post-Operative Opioid Use after Anterior Cruciate Ligament Reconstruction: A Review of Level I Evidence.

Authors:
Neeraj Vij Olivia Newgaard Matt Norton Hannah Tolson Alan D Kaye Omar Viswanath Ivan Urits

Orthop Rev (Pavia) 2022 5;14(3):37159. Epub 2022 Aug 5.

Department of Anesthesiology, Louisiana State University Health Shreveport.

Introduction: Anterior Cruciate Ligament tears are common after a non-contact injury and several thousand reconstructions (ACLR) occur yearly in the United States. Multimodal pain management has evolved greatly to include nerve blocks to minimize physical therapy losses post-operatively, pericapsular and wound injections, and other adjunctive measures. However, there is a surprisingly high use of opioid use after ACLR. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

The role for high volume local infiltration analgesia with liposomal bupivacaine in total hip arthroplasty: A scoping review.

Authors:
Neeraj Vij Rajesh Supra Delena Vanvalkenburg Nicholas Comardelle Alan D Kaye Omar Viswanath Ivan Urits

Orthop Rev (Pavia) 2022 5;14(3):37101. Epub 2022 Aug 5.

Department of Anesthesiology, Louisiana State University Health Shreveport.

Introduction: Liposomal bupivacaine has been integrated into clinical practice within many surgical disciplines to reduce post-operative pain and opioid consumption. This novel agent has been utilized in this regard in many subdisciplines of orthopedic surgery. Total hip arthroplasty has significant opioid use post-operatively as compared to many other orthopedic disciplines. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Predictors and trends of opioid-sparing radical prostatectomy from a large national cohort.

Authors:
Aaron Brant Patrick Lewicki Jeffrey P Johnson Ilon C Weinstein Anise Bowman Christina Sze Jonathan E Shoag

Urology 2022 Aug 2. Epub 2022 Aug 2.

Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, 9501 Euclid Ave, Cleveland, OH 44106, USA. Electronic address:

Objective: To examine the use of pain medications after radical prostatectomy using a large national database.

Methods: The Premier Hospital Database was queried to identify all robotic and laparoscopic radical prostatectomies from January 2015 - March 2020 with length of stay ≥1 day. "Opioid-sparing" was defined as absence of intravenous opioid use after post-operative day 0 and absence of oral opioid use throughout admission. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Block duration is substantially longer with a liposomal suspension of bupivacaine than with 0.5% bupivacaine HCl potentiated with dexmedetomidine following an ultrasound-guided sciatic nerve block in Beagles.

Authors:
Luis Campoy Manuel Martin-Flores Robin D Gleed Laci C Taylor Jilliant E Yant Rhiannon Pavlinac

Am J Vet Res 2022 Jun 21;83(8). Epub 2022 Jun 21.

College of Veterinary Medicine, Cornell University, Ithaca, NY.

Objective: To compare the duration of bupivacaine liposome suspension in the dog with that of bupivacaine and dexmedetomidine following a perineural injection.

Animals: 8 healthy Beagles.

Procedures: The left sciatic nerve of each dog was randomly assigned to an ultrasound-guided perineural injection with either bupivacaine liposome suspension (BLS) or with 0. Read More

View Article and Full-Text PDF
June 2022
Similar Publications
}